Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
ViaCyte logo — Regenerating Health: Transforming the lives of patients with...

ViaCyte

Regenerating Health: Transforming the lives of patients with insulin-requiring diabetes

Founded 1999 United States San Diego, United States 35 employees Series D Total: $235.55M Biotechnology, Health Care +1

General Information

Company Name ViaCyte
Founded Year 1999
Location United States San Diego, United States +1
Founders / Decision Makers
Team member Team member Team member
Employees 35
Industries Biotechnology, Health Care, Health and Wellness
Funding Stage Series D
Social

Get notified when ViaCyte moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About ViaCyte

ViaCyte is a biotechnology startup from the United States, focused on developing revolutionary cell replacement therapies for long-term diabetes treatment, aiming to achieve glucose control targets and reduce the risk of hypoglycemia and diabetes-related complications. ViaCyte's product candidates are rooted in the directed differentiation of pluripotent stem cells into PEC-01 pancreatic islet progenitor cells, implanted in durable and retrievable cell delivery devices. The company has garnered attention through its collaborative partnerships with esteemed companies such as CRISPR Therapeutics and W.L. Gore & Associates, aiming to accelerate and expand its efforts. ViaCyte's pipeline includes the PEC-Direct product candidate, which is currently undergoing clinical evaluation and delivers PEC-01 cells in a non-immunoprotective device, catering to type 1 diabetes patients with specific conditions. Additionally, the PEC-Encap product candidate delivers pancreatic islet progenitor cells in an immunoprotective device, intended for all type 1 diabetes patients. Recently, ViaCyte attracted a Series D investment on 22 April 2021, with notable backers including Invus, Adage Capital Management, Asymmetry Ventures, and Artis Ventures (AV). The company showcases promising potential with its emphasis on regenerative medicine, aiming to transform the lives of patients with insulin-requiring diabetes, making it a compelling prospect for venture capital investment.

Taxonomy: Regenerative Medicine, Cell Therapy, Diabetes Treatment, Stem Cell Therapy, Pancreatic Islet Progenitor Cells, Type 1 Diabetes, Insulin Replacement Therapy, Clinical Evaluation, Immuno-evasive Therapy, Collaborative Partnerships, CRISPR Therapeutics, W.L. Gore & Associates, Chronic Disease Management, Medical Device Innovation, Cell Differentiation

Funding Rounds & Investors (15)

View All
Funding Stage Amount Investors Lead Investors Date
Series D •••••• 4
Investor Investor Investor
•••• •••• 		22 Apr 2021
Series D •••••• 4
Investor Investor
•••• •••• 		20 Mar 2020
Series D •••••• 4
Investor Investor
•••• •••• 		29 Nov 2018
Convertible Note •••••• 1 •••• •••• 25 Sep 2018
Grant •••••• 1 •••• •••• 17 Apr 2018

View All 15 Funding Rounds

FAQ About ViaCyte

Regenerating Health: Transforming the lives of patients with insulin-requiring diabetes
ViaCyte was founded in 1999.
ViaCyte is headquartered in San Diego, United States.
ViaCyte operates in the following industries: Biotechnology, Health Care, Health and Wellness.
ViaCyte has approximately 35 employees.
ViaCyte has completed 15 funding rounds, raising a total of $235.55M. The latest funding stage is Series D.

We're actively collecting intelligence on ViaCyte.

Track ViaCyte to get notified

Don't just browse. Track.

Signal Tracker monitors ViaCyte and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy

Book a demo 30 minutes